# YARW earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/YARW) · [Earnings tab](https://www.lopjlb.com/stock/YARW?tab=earnings) Updated: 2026-08-13T06:03:40 Quarters analyzed: 6 ## Cross-quarter narrative Across the 2020‑2021 earnings calls YARW’s story moved from a launch‑centric, COVID‑disrupted commercial phase to a strategic pivot toward R&D and divestiture of its minocycline franchise. Early 2020 calls highlighted strong initial uptake of AMZEEQ, a steep COVID‑driven dip in prescriptions, and aggressive cost‑cutting to extend cash runway to Q2 2021. By Q2‑Q3 2020 the company secured ZILXI approval, raised equity, and reported prescription rebounds, yet uncertainty around FCD105 outcomes and payer formulary exclusions persisted. In 2021 the tone shifted: field access remained limited by pandemic protocols, CVS Caremark exclusion trimmed covered lives, and cash runway was extended to Q2 2022. Management announced a transition to an R&D‑focused model, exploring sale of the minocycline franchise while advancing BET‑inhibitor programs (VYN201, VYN202) and FMX114. Safety concerns for oral BET inhibitors and FDA labeling risk for JAK‑class drugs emerged as new worries. Throughout, cash management, payer dynamics, and COVID‑related market access remained recurring themes, while the franchise divestiture and BET pipeline represent new strategic directions. ## Latest CallCard · Q3 VYNE Therapeutics advances immuno-inflammatory pipeline with BET inhibitor platform (VYN201 topical, VYN202 oral) targeting 2022 INDs, FMX114 Phase 1b/2a top-line data expected early Q1 2022, and minocycline franchise sale progressing; cash runway through Q2 2022. **Guidance:** maintained — Provided specific adjusted operating expense guidance: Q4 2021 $10-15M (excl. $4M milestone), 2022 ~$10M/quarter; cash runway through Q2 2022 without franchise sale proceeds. **Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks emphasize achieved milestones, excitement about BET platform, positive preclinical data, and clear near-term catalysts; language is confident and forward-looking. ### Demand visibility Minocycline franchise shows prescription growth but is being divested; pipeline programs are pre-clinical/early clinical with limited demand visibility. AMZEEQ and ZILXI combined ~165k prescriptions through Sep 2021; sale of franchise in progress with interest; BET inhibitor programs pre-clinical; FMX114 Phase 1b/2a top-line data expected early Q1 2022. ### Margins / costs Operating expenses declining as focus shifts to pipeline; cash runway through Q2 2022 without franchise sale proceeds. Q3 adjusted op ex $18.4M ($11.9M SG&A, $6.5M R&D), down $1.9M from Q2; Q4 guidance $10-15M plus $4M milestone; 2022 ~$10M/quarter; cash $53M at Sep 30. ### Capital allocation Divesting minocycline franchise to fund pipeline development; focusing R&D on BET inhibitors (VYN201, VYN202) and FMX114. Sale of minocycline franchise (AMZEEQ, ZILXI, FCD105, MST platform) in progress with interest; cash $53M funds ops through Q2 2022; adjusted op ex targeted ~$10M/quarter in 2022 for clinical advancement. ### Milestones - **VYN201 (topical pan-BET inhibitor)** [on_track]: Formulation selected; preclinical safety program underway; IND planned for 2022; positive preclinical data in imiquimod model, human skin tissue, and skin healing models. - **VYN202 (oral BD2-selective BET inhibitor)** [on_track]: Lead optimization with In4Derm progressing; candidate selection ongoing; IND-enabling non-clinical safety program to follow final candidate selection. - **FMX114 (topical tofacitinib/fingolimod gel for atopic dermatitis)** [on_track]: Phase 1b/2a trial enrolled first patient Oct 2021; top-line results expected early Q1 2022; PK data expected before year-end. - **Minocycline franchise divestiture (AMZEEQ, ZILXI, FCD105, MST platform)** [on_track]: Sale process advancing with encouraging interest; updates to be provided as discussions continue. - **Scientific Advisory Board formation** [delivered]: Board of world-renowned experts in immunological/inflammatory diseases formed; first meeting held last month with broad agreement on BET platform utility. - **VYN201 preclinical data package** [delivered]: Positive data across multiple models: 94% reduction in clinical signs vs vehicle in imiquimod model, comparable to clobetasol; >95% cytokine inhibition in human skin tissue; no negative impact on wound healing; reduced fibrotic tissue mass. - **Cash runway** [on_track]: Cash of $53M at Sep 30, 2021 expected to fund operations through Q2 2022, excluding potential franchise sale proceeds or financing. ### Fears / risks - **BET inhibitor class safety**: Oral pan-BD BET inhibitors associated with thrombocytopenia, GI toxicities, emesis; VYN201 mitigated by topical route and designed metabolic liability; VYN202 mitigated by BD2 selectivity. - **JAK inhibitor class labeling impact**: Recent FDA class labeling for oral JAK inhibitors may create perception risk for FMX114 despite topical delivery; management believes dermatologists are accustomed to such labels. - **Minocycline franchise sale uncertainty**: Timing and proceeds of sale are uncertain; cash runway projection excludes these proceeds. - **Cash runway limitation**: Cash sufficient only through Q2 2022 without franchise sale, BD transactions, or additional financing. - **Early-stage pipeline indication risk**: BET programs are pre-clinical; final indication selection not yet locked; preclinical efficacy may not translate to clinical success. - **Competitive landscape in atopic dermatitis**: Topical JAK inhibitors (e.g., Incyte's approved product) already in market; FMX114 must demonstrate differentiated multimodal benefit. - **Partner dependence for VYN202**: VYN202 development relies on In4Derm for lead optimization and candidate selection. ### Key quotes > “Without question, the catalytic event driving this transformation has been the licensing of our Bromodomain and Extra-Terminal or BET Inhibitor Platform which we announced in August.” > “Our focus will be to advance our lead topical BETi inhibitor product candidates, VYN201 into the clinic in 2022.” > “We believe that this cash will be sufficient to fund our operations through the second quarter of 2022.” > “VYN201 significantly reduces the expression of several key for inflammatory cytokines relevant to Th17 mediated autoimmune diseases, and has demonstrated improvement in reducing fibrotic tissue masks, and overall skin repair outcomes.” > “The fact we solved that level of response in line with what you see from Clobetasol super potent steroid, Yet initial tolerant -- tolerability data being very positive and encouraging just gives us a lot of enthusiasm about” ## Quarter one-liners - **2021 Q3:** VYNE Therapeutics advances immuno-inflammatory pipeline with BET inhibitor platform (VYN201 topical, VYN202 oral) targeting 2022 INDs, FMX114 Phase 1b/2a top-line data expected early Q1 2022, and minocycline franchise sale progressing; cash runway through Q2 2022. - **2021 Q2:** VYNE Therapeutics shifts strategy to R&D focus, exploring sale/license of minocycline franchise (AMZEEQ/ZILXI) while advancing BETi pipeline via In4Derm licensing and FMX114 Phase 2a. - **2021 Q1:** VYNE Q1 revenue $4.1M, cash $120.4M; AMZEEQ/ZILXI market access 70-75% after CVS Caremark exclusion; FMX114 Phase 2a start Q3, FCD105 Phase 3 ready but timing uncertain. - **2020 Q3:** VYNE Therapeutics reports strong Q3 growth for AMZEEQ, launches ZILXI, sees expanding payer coverage, but faces uncertainty around FCD105 Phase 2 outcomes and COVID‑related market access. - **2020 Q2:** Menlo Therapeutics launched AMZEEQ, gained FDA approval for ZILXI (rosacea), raised $54M equity, amended credit terms, and targets Q4 ZILXI launch with cash runway through 2021. - **2020 Q1:** Menlo launched AMZEEQ Jan 2020; FMX103 PDUFA June 2; FCD105 Phase II readout imminent; COVID-19 slowed launch but prescriptions stabilizing; cost cuts extend cash runway to Q2 2021. ## Theme arcs - **COVID-19 impact** (improving): Prescription volumes rebounded and field access improved, though occasional spikes still limited sales activities - **Payer formulary exclusion** (deteriorating): CVS Caremark exclusion reduced covered commercial lives to 70‑75% and persisted into 2021 - **Cash runway** (improving): Equity raise and cost cuts extended runway from Q2 2021 to Q2 2022 - **Minocycline franchise commercialization** (new): Shift from growth to exploration of sale/license of AMZEEQ, ZILXI, and related assets - **Pipeline focus shift** (new): Company reallocated capital to BET inhibitor and FMX114 programs - **FCD105 development risk** (stable): Phase II readout delivered but Phase III remains at risk with no clear timeline - **BET inhibitor safety concerns** (new): Oral pan‑BET class safety signals highlighted as a fresh risk - **JAK inhibitor labeling risk** (new): Recent FDA class labeling for oral JAK inhibitors may affect perception of FMX114 despite topical delivery ## Guidance path 2020 Q1:vague → 2020 Q2:vague → 2020 Q3:maintained → 2021 Q1:vague → 2021 Q2:vague → 2021 Q3:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/YARW`